bioMerieux SA

BIM

Equity

ISIN FR0013280286 / Valor 38147803

Euronext - Euronext Paris (2026-09-04)

EUR 74.25-2.24%

bioMerieux SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

bioMérieux SA is a global leader in the field of in vitro diagnostics, providing a wide range of diagnostic solutions to healthcare providers. The company specializes in the development, production, and marketing of diagnostic systems and services that are used in clinical applications. Among its innovative offerings, bioMérieux provides the VIDAS® KUBE™, an advanced automated immunoassay solution that enhances laboratory operations with its flexibility and cost-effectiveness. Additionally, the company offers SPOTFIRE®, a multiplex PCR solution tailored for point-of-care testing that delivers rapid, onsite actionable results, and VITEK® MS PRIME, which leverages mass spectrometry technology to improve daily laboratory workflows and patient care, particularly in the critical area of sepsis management. bioMérieux's commitment to advancing healthcare is evident in its comprehensive approach to sepsis management, offering solutions that support the entire process from antibiotic initiation through to appropriate discontinuation. Through its focus on innovation and efficiency, bioMérieux SA plays a crucial role in enhancing diagnostic capabilities and improving patient outcomes worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Sales overview (H1 & Q2 2026)

H1 2026 sales €1,965m, organic +0.2%. Q2 2026 sales €981m, organic +5% (+7% excluding BIOFIRE® respiratory panels).

Performance by pillar

GO•28 growth drivers up ~+6% organic in H1; Microbiology +4.3% (strong reagent and BACT/ALERT® bottle momentum); SPOTFIRE® revenue €90m with reagents +35%; BIOFIRE® non‑respiratory panels +5.5% (Q2 acceleration); Industrial Applications +7%.

BIOFIRE® respiratory headwind

BIOFIRE® respiratory panels declined -17% organically in H1 2026 due to a significantly softer respiratory season versus H1 2025, materially impacting overall growth.

Profitability (CEBIT)

Contributive operating income before non‑recurring items (CEBIT) of €313m in H1 2026, negatively affected by a €35m currency headwind and down -4.9% organically versus H1 2025.

Net income & EPS

Net income (group share) €226m, up 41% YoY (prior year included a partial impairment of VITEK® REVEAL™). Adjusted diluted EPS €1.99, -4% on an organic basis and -17% reported versus H1 2025.

Cash flow

Free cash flow strongly improved to €299m in H1 2026, a +76% increase versus H1 2025.

Guidance for 2026

bioMerieux confirmed 2026 guidance: organic sales growth expected +3% to +5% and organic CEBIT growth +0% to +10%. Full‑year 2026 negative currency effect on CEBIT now expected at €40–50m (previously €50–60m).

Midterm outlook (2027–2028)

Company adjusted its midterm targets: now targeting +3% to +6% organic annual sales growth for 2027–2028 (versus prior 7% CAGR for 2024–2028) and organic annual CEBIT growth higher than organic sales growth (vs prior “at least +10%”).

Operational milestones

Q2 2026 achievements include FDA submission of the SPOTFIRE® vaginitis panel and CE marking of the first SPINCHIP® assay, underlining ongoing innovation progress.

Summarized from source with an LLMView Source

Key figures

-35.8%1Y

-22.4%3Y

-32.9%5Y

Performance

31.4%1Y

25.6%3Y

27.5%5Y

Volatility